Index
Module 5 • Medication Safety
Pharmacoeconomics & Safe Medication Use
12%
Data Tables
Pharmacoeconomics & Safe Medication Use
Adrian Wong ~2 min read Module 5 of 20
4
/ 33

Pharmacoeconomics and Safe Medication Use

B.Integrating interruptive clinical decision sup-

port (CDS) into the EHR.

C.Creating a policy requiring that intrave-

nous medications can only be prepared by

pharmacists.

D.Investing in smart intravenous infusion pumps

to reduce medication errors.

6

After your institution has integrated your recom-

mendation into routine medical care, a former

patient recommends including the patient and other

caregivers in reducing medication errors. According

to the available literature, which best supports this

recommendation?

A.The 2017 SCCM guidelines provide a strong

recommendation for this integration into rou-

tine care.

B.Areas in the hospital outside the ICU provide

data supporting this integration.

C.Data analyses on direct observations of inter-

actions between the medical team and patients

have shown a reduction in medical errors in the

ICU.

D.Data analyses on chart reviews of ICU patients

have shown that these reported outcomes are

not routinely accounted for.

7

A 50-year-old patient was initiated on meropenem

for empiric coverage of pneumonia, given prior

culture data. They were subsequently initiated on

valproic acid for the management of agitation; how-

ever, this was not effective for management and

resulted in self-extubation and subsequent reintu-

bation. In investigating this adverse event, which

method would best evaluate the likelihood of its

occurrence?

A.Drug interaction database.
B.Drug interaction probability scale.
C.Naranjo nomogram.
D.Roussel Uclaf Causality Assessment Method

(RUCAM).

8

Your hospital wants to add meropenem/vaborbac-

tam, a broad-spectrum antimicrobial targeting highly

drug-resistant organisms that is FDA approved for

complicated UTIs, to the formulary. Which would

be the most appropriate restriction to its use?

A.Restriction to intensivist use.
B.Restriction to patients with hospital-acquired

pneumonia.

C.Restriction to infectious diseases clinicians’

approval.

D.Restriction to patients with appropriate cardiac

monitoring.

Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 3 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube